dexrazoxane has been researched along with Benign Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Aghdam, M; Crooks, BN; Giacomantonio, N; Grandy, SA; Heinze-Milne, S; Johnston, WJ; Keats, MR; Kendall, SJ; Langley, JE; Mulvagh, SL | 1 |
| Amin Hashemipour, SM; Hosseinpour, H; Keshavarzian, E; Khamas, SS; Kogani, M; Moazen, M; Mortazavizadeh, SM; Motevalipoor, AF; Sadighpour, T; Soltani, M; Valizadeh, R | 1 |
| Armenian, SH; de Baat, EC; Feijen, EAM; Kremer, LCM; Mavinkurve-Groothuis, AMC; Mulder, RL; van Dalen, EC | 1 |
| Corrêa, FM; Fernandes, RRA; Freitas, PG; Guerra, RL; Vianna, CMM | 1 |
| Amdani, S; Bansal, N; Lipshultz, ER; Lipshultz, SE | 1 |
| Chan, M; Chiu, B; Harris, J; Liesse, K; Schmidt, ML | 1 |
| Ahn, HS; Baek, HJ; Cho, B; Choi, HS; Chueh, HW; Chung, NG; Hah, JO; Hahn, S; Im, HJ; Kang, HJ; Kawano, Y; Kim, H; Kim, HK; Kim, HM; Kim, HS; Kim, JY; Koh, KN; Kook, H; Lee, JA; Lee, JM; Lee, JW; Lee, MJ; Lee, YH; Park, JW; Park, KD; Park, M; Park, SK; Seo, JJ; Shin, HY; Yoon, HS | 1 |
| Colan, SD; Franco, VI; Lipshultz, SE; Miller, TL; Sallan, SE | 1 |
| Almanric, K; Boulanger, J; Ducharme, A; Dufour, A; Fortier, S | 1 |
| Koshihara, N; Maruyama, K | 1 |
| Franco, VI; Lipshultz, SE | 1 |
| Chen, JJ; Middlekauff, HR; Nguyen, KL; Wu, PT | 1 |
| Abdel-Qadir, H; Amir, E; Fazelzad, R; Lee, DS; Ong, G; Thavendiranathan, P; Tomlinson, G | 1 |
| Fujita, H; Izumo, T; Kadono, H; Katori, T; Kawamoto, S; Okamoto, R; Shirahata, T | 1 |
10 review(s) available for dexrazoxane and Benign Neoplasms
| Article | Year |
|---|---|
The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review.
Topics: Anthracyclines; Cancer Survivors; Cardiotoxicity; Dexrazoxane; Heart Diseases; Humans; Neoplasms; Survivors | 2022 |
Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiotoxicity; Dexrazoxane; Humans; Idarubicin; Neoplasms | 2023 |
Chemotherapy-induced cardiotoxicity in children.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasms; Primary Prevention; Risk Factors | 2017 |
Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
Topics: Adolescent; Anthracyclines; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Disease-Free Survival; Female; Humans; Infant; Male; Neoplasms; Survival Rate | 2018 |
Cardiovascular disease in adult survivors of childhood cancer.
Topics: Adult; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Cardiovascular Diseases; Child; Dexrazoxane; Doxorubicin; Humans; Neoplasms; Survivors | 2015 |
Management of the extravasation of anti-neoplastic agents.
Topics: Antineoplastic Agents; Catheterization, Central Venous; Catheterization, Peripheral; Dexrazoxane; Dimethyl Sulfoxide; Extravasation of Diagnostic and Therapeutic Materials; Humans; Hyaluronoglucosaminidase; Neoplasms; Quebec; Risk Factors; Thiosulfates | 2015 |
[Pharmacological and clinical profile of dexrazoxane (SAVENE® Intravenous Infusion 500 mg), a therapeutic agent for anthracycline extravasation].
Topics: Animals; Anthracyclines; Clinical Trials as Topic; Dexrazoxane; Humans; Infusions, Intravenous; Neoplasms; Skin Ulcer | 2015 |
Cardiac complications in childhood cancer survivors treated with anthracyclines.
Topics: Anthracyclines; Antineoplastic Agents; Cardiotoxicity; Dexrazoxane; Heart Failure; Humans; Neoplasms; Pediatrics; Risk Factors; Survivors | 2015 |
Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
Topics: Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Exercise; Exercise Therapy; Heart Diseases; Humans; Neoplasms; Survivors | 2017 |
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Cardiomyopathies; Clinical Trials as Topic; Dexrazoxane; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Network Meta-Analysis; Prenylamine; Ventricular Dysfunction, Left | 2017 |
4 other study(ies) available for dexrazoxane and Benign Neoplasms
| Article | Year |
|---|---|
Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Humans; Neoplasms; Polyketides; Razoxane | 2023 |
[Economic assessment of dexrazoxane in prophylaxis of cardiotoxicity in children undergoing chemotherapy with anthracyclines].
Topics: Age Factors; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Cost-Benefit Analysis; Dexrazoxane; Female; Heart; Heart Failure; Humans; Male; Neoplasms | 2019 |
Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
Topics: Adolescent; Adult; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Factor Analysis, Statistical; Female; Humans; Incidence; Infant; Infant, Newborn; Male; Multivariate Analysis; Neoplasms; Neoplasms, Second Primary; Republic of Korea; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2019 |
[Effectiveness of Dexrazoxane for Extravasation of Anthracycline Antitumor Antibiotics - Reporting Measures Developed against Extravasation in the Hospital].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Dexrazoxane; Extravasation of Diagnostic and Therapeutic Materials; Female; Hospitals; Humans; Middle Aged; Neoplasms | 2016 |